BofA/Merrill Lynch Downgrades Adamas Pharmaceuticals (ADMS) to Neutral
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Price: $8.22 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA/Merrill Lynch analyst Tazeen Ahmad downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Buy to Neutral with a price target of $25.00 (from $36.00).
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $19.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
- Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
